抗けいれん薬市場：薬物タイプ別、適応症別-2025～2030年の世界予測

抗けいれん薬市場は、2023年に120億3,000万米ドルと評価され、2024年には130億7,000万米ドルに達すると予測され、CAGR 8.71%で成長し、2030年には215億9,000万米ドルに達すると予測されています。

抗てんかん薬としても知られる抗けいれん薬は、主にてんかんに伴う発作の予防と治療に使用される医薬品であるが、双極性障害、片頭痛、神経障害性疼痛にも使用されます。抗けいれん薬の必要性は、神経疾患の有病率の増加と、そのような状態の効果的な管理の必要性に由来します。これらの薬剤は、病院、クリニック、在宅医療の現場で幅広く使用されており、てんかんやその他の神経疾患の患者に重要な治療選択肢を提供しています。最終用途の範囲は医療プロバイダーと患者に大きく広がっており、服薬アドヒアランスと副作用管理に関するアクセシビリティと患者教育の必要性を裏付けています。市場の成長は、創薬における技術的進歩、診断能力の向上、これらの薬に対する認識と受容の高まりによって大きく左右されます。さらに、新規製剤や併用療法の漸進的な出現は、市場浸透の潜在的機会を提供しています。しかし、厳しい規制の枠組み、潜在的な副作用、高額な治療費といった課題は、市場の成長を妨げる可能性があります。薬剤耐性てんかんに対する適切な治療にはまだ顕著なギャップがあり、技術革新と研究の潜在領域が浮き彫りになっています。さらに、個別化医療アプローチの開発や薬剤開発に人工知能を活用することで、有効性の向上と副作用の最小化を目指した事業成長の新たな道が開ける可能性があります。抗けいれん薬市場の性質を考慮すると、企業は戦略的パートナーシップ、先進的研究開発への投資、市場の多様化を優先し、関連性を維持する必要があります。経皮パッチや経鼻スプレーのような送達方法における絶え間ない技術革新や、新たな作用機序の探求は、市場の力学に大きな影響を与え、成長を促進し、神経治療におけるアンメットニーズに対応することができます。

市場力学：急速に進化する抗けいれん薬市場の主要市場洞察を公開

抗けいれん薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 若年層と高齢者層におけるてんかん有病率の増加
  • てんかんの啓発を支援する政府イニシアチブの高まり
  • てんかん以外の疾患の治療における使用拡大
• 市場抑制要因
  • 疼痛管理の代替オプションの利用可能性
• 市場機会
  • 規制当局による抗てんかん薬の承認増加
  • 新世代の抗てんかん薬の登場
• 市場課題
  • 薬剤供給不足と第二世代薬剤の特許切れ

ポーターのファイブフォース：抗けいれん薬市場をナビゲートする戦略ツール

ポーターのファイブフォース：」フレームワークは、市場情勢の競合情勢を把握するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：抗けいれん薬市場における外部からの影響の把握

外部マクロ環境要因は、抗けいれん薬市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：抗けいれん薬市場における競合情勢の把握

抗けいれん薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：抗けいれん薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、抗けいれん薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：抗けいれん薬市場における成功への道筋を描く

抗けいれん薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 若者と高齢者の間でてんかんの罹患率が増加
    • てんかん啓発を支援する政府の取り組みが増加
    • 非てんかん性疾患の治療における使用拡大
  • 抑制要因
    • 疼痛管理の代替オプションの利用可能性
  • 機会
    • 規制当局による抗けいれん薬の承認増加
    • 新世代抗てんかん薬の登場
  • 課題
    • 医薬品供給不足と第二世代医薬品の特許切れ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 抗けいれん薬市場：薬剤タイプ別

• イントロダクション
• AMPA
• バルビツール酸
• ベンゾジアゼピン
• カルバメート抗けいれん薬
• 炭酸脱水酵素阻害剤
• ジベンザゼピン
• トリアジン

第7章 抗けいれん薬市場：適応症別

• イントロダクション
• 不安
• 双極性障害
• 境界性人格障害
• てんかん
• 線維筋痛症
• 片頭痛
• 神経障害性疼痛

第8章 南北アメリカの抗けいれん薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋の抗けいれん薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの抗けいれん薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Astrazeneca PLC
• Bausch Health Companies Inc.
• Biocon Limited
• Cadila Pharmaceuticals Limited
• Cipla, Inc.
• Dr. Reddy's Laboratories Limited
• Eisai Co., Ltd.
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Ltd.
• Jazz Pharmaceuticals, Inc.
• Johnson & Johnson Services, Inc.
• Lifecare Neuro Products Limited
• Lundbeck A/S
• Mankind Pharma Ltd.
• Merck KGaA
• Novartis AG
• Novo Nordisk A/S
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer Inc.
• Sanofi S.A.
• Sunovion Pharmaceuticals Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.
• Wockhardt Limited

LIST OF FIGURES

• FIGURE 1. ANTICONVULSANTS MARKET RESEARCH PROCESS
• FIGURE 2. ANTICONVULSANTS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTICONVULSANTS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTICONVULSANTS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTICONVULSANTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTICONVULSANTS MARKET DYNAMICS
• TABLE 7. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTICONVULSANTS MARKET SIZE, BY AMPA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BARBITURATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBAMATE ANTICONVULSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTICONVULSANTS MARKET SIZE, BY CARBONIC ANHYDRASE INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTICONVULSANTS MARKET SIZE, BY DIBENZAZEPINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTICONVULSANTS MARKET SIZE, BY TRIAZINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTICONVULSANTS MARKET SIZE, BY ANXIETY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BIPOLAR DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTICONVULSANTS MARKET SIZE, BY BORDERLINE PERSONALITY DISORDER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTICONVULSANTS MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTICONVULSANTS MARKET SIZE, BY FIBROMYALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTICONVULSANTS MARKET SIZE, BY MIGRAINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTICONVULSANTS MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ANTICONVULSANTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 40. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. CHINA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 43. CHINA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 44. INDIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 45. INDIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 46. INDONESIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 47. INDONESIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 48. JAPAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 49. JAPAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 50. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 51. MALAYSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 52. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 53. PHILIPPINES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 54. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 55. SINGAPORE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 57. SOUTH KOREA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 58. TAIWAN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 59. TAIWAN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 60. THAILAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 61. THAILAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. VIETNAM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 63. VIETNAM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 64. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 65. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 66. EUROPE, MIDDLE EAST & AFRICA ANTICONVULSANTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 67. DENMARK ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 68. DENMARK ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 69. EGYPT ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 70. EGYPT ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 71. FINLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 72. FINLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 73. FRANCE ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 74. FRANCE ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. GERMANY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 76. GERMANY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 77. ISRAEL ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 78. ISRAEL ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 79. ITALY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 80. ITALY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 81. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 82. NETHERLANDS ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. NIGERIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 84. NIGERIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 85. NORWAY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 86. NORWAY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. POLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 88. POLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 89. QATAR ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 90. QATAR ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 91. RUSSIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 92. RUSSIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 93. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 94. SAUDI ARABIA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 95. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 96. SOUTH AFRICA ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 97. SPAIN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 98. SPAIN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 99. SWEDEN ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 100. SWEDEN ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 102. SWITZERLAND ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 103. TURKEY ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 104. TURKEY ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 105. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 106. UNITED ARAB EMIRATES ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 107. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
• TABLE 108. UNITED KINGDOM ANTICONVULSANTS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. ANTICONVULSANTS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 110. ANTICONVULSANTS MARKET, FPNV POSITIONING MATRIX, 2023

The Anticonvulsants Market was valued at USD 12.03 billion in 2023, expected to reach USD 13.07 billion in 2024, and is projected to grow at a CAGR of 8.71%, to USD 21.59 billion by 2030.

Anticonvulsants, also known as antiepileptic drugs, are medications primarily used to prevent and treat seizures associated with epilepsy but are also used for bipolar disorder, migraines, and neuropathic pain. The necessity for anticonvulsants stems from the increasing prevalence of neurological disorders and the need for effective management of such conditions. These medications find broad application across hospitals, clinics, and homecare settings, offering critical therapeutic options for patients with epilepsy and other neurological conditions. The end-use scope largely extends to healthcare providers and patients, underlining the need for accessibility and patient education regarding medication adherence and side effects management. Market growth is significantly influenced by technological advancements in drug discovery, an increase in diagnostic capabilities, and heightened awareness and acceptance of these medications. Moreover, the progressive emergence of novel drug formulations and combination therapies offers potential opportunities for deeper market penetration. However, challenges such as stringent regulatory frameworks, potential side effects, and the high cost of treatment may hamper market growth. There is still a notable gap in adequate treatment for drug-resistant forms of epilepsy, highlighting a potential area for innovation and research. Furthermore, developing personalized medicine approaches and leveraging artificial intelligence for drug development could present new avenues for business growth, aiming to increase efficacy and minimize adverse effects. Given the nature of the anticonvulsants market, characterized by a competitive landscape with numerous players focusing on R&D and mergers, businesses must prioritize strategic partnerships, investment in advanced R&D, and market diversification to stay relevant. Continuous innovation in delivery methods, like transdermal patches or intranasal sprays, and exploring novel mechanisms of action can significantly influence market dynamics, propelling growth and addressing unmet needs in neurological treatment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Anticonvulsants Market

The Anticonvulsants Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of epilepsy among young and senior population
  • Rising government initiatives supporting epilepsy awareness
  • Expanding use in treating nonepileptic conditions
• Market Restraints
  • Availability of substitutes options for pain management
• Market Opportunities
  • Rising drug approvals of anticonvulsant drugs from regulatory bodies
  • Emergence of new-generation antiepileptic drugs
• Market Challenges
  • Drug supply shortage and patent expiration of the second-generation drugs

Porter's Five Forces: A Strategic Tool for Navigating the Anticonvulsants Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Anticonvulsants Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Anticonvulsants Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Anticonvulsants Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Anticonvulsants Market

A detailed market share analysis in the Anticonvulsants Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Anticonvulsants Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Anticonvulsants Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Anticonvulsants Market

A strategic analysis of the Anticonvulsants Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Anticonvulsants Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astrazeneca PLC, Bausch Health Companies Inc., Biocon Limited, Cadila Pharmaceuticals Limited, Cipla, Inc., Dr. Reddy's Laboratories Limited, Eisai Co., Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Jazz Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Lifecare Neuro Products Limited, Lundbeck A/S, Mankind Pharma Ltd., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Sunovion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Wockhardt Limited.

Market Segmentation & Coverage

This research report categorizes the Anticonvulsants Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug types, market is studied across AMPA, Barbiturate, Benzodiazepine, Carbamate Anticonvulsants, Carbonic Anhydrase Inhibitor, Dibenzazepine, and Triazine.
• Based on Indication, market is studied across Anxiety, Bipolar Disorder, Borderline Personality Disorder, Epilepsy, Fibromyalgia, Migraine, and Neuropathic Pain.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of epilepsy among young and senior population
    • 5.1.1.2. Rising government initiatives supporting epilepsy awareness
    • 5.1.1.3. Expanding use in treating nonepileptic conditions
  • 5.1.2. Restraints
    • 5.1.2.1. Availability of substitutes options for pain management
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising drug approvals of anticonvulsant drugs from regulatory bodies
    • 5.1.3.2. Emergence of new-generation antiepileptic drugs
  • 5.1.4. Challenges
    • 5.1.4.1. Drug supply shortage and patent expiration of the second-generation drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Anticonvulsants Market, by Drug types

• 6.1. Introduction
• 6.2. AMPA
• 6.3. Barbiturate
• 6.4. Benzodiazepine
• 6.5. Carbamate Anticonvulsants
• 6.6. Carbonic Anhydrase Inhibitor
• 6.7. Dibenzazepine
• 6.8. Triazine

7. Anticonvulsants Market, by Indication

• 7.1. Introduction
• 7.2. Anxiety
• 7.3. Bipolar Disorder
• 7.4. Borderline Personality Disorder
• 7.5. Epilepsy
• 7.6. Fibromyalgia
• 7.7. Migraine
• 7.8. Neuropathic Pain

8. Americas Anticonvulsants Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Anticonvulsants Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Anticonvulsants Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Astrazeneca PLC
• 3. Bausch Health Companies Inc.
• 4. Biocon Limited
• 5. Cadila Pharmaceuticals Limited
• 6. Cipla, Inc.
• 7. Dr. Reddy's Laboratories Limited
• 8. Eisai Co., Ltd.
• 9. GlaxoSmithKline PLC
• 10. Glenmark Pharmaceuticals Ltd.
• 11. Jazz Pharmaceuticals, Inc.
• 12. Johnson & Johnson Services, Inc.
• 13. Lifecare Neuro Products Limited
• 14. Lundbeck A/S
• 15. Mankind Pharma Ltd.
• 16. Merck KGaA
• 17. Novartis AG
• 18. Novo Nordisk A/S
• 19. Otsuka Pharmaceutical Co., Ltd.
• 20. Pfizer Inc.
• 21. Sanofi S.A.
• 22. Sunovion Pharmaceuticals Inc.
• 23. Takeda Pharmaceutical Company Limited
• 24. Teva Pharmaceutical Industries Ltd.
• 25. Wockhardt Limited